K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways
Authors:
- Paul M. CampbellPCPaul M. Campbell
- Rolf A. BrekkenRBRolf A. Brekken
- Bokyung SungBSBokyung Sung
- Michel M. OuelletteMOMichel M. Ouellette
- Jason B. FlemingJFJason B. Fleming
- Bharat B. AggarwalBABharat B. Aggarwal
- Channing J. DerCDChanning J. Der
- Sushovan GuhaSGSushovan Guha
- 23 June 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 7 (6) , 799-808
Abstract
Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease. However, the function of mutant K-Ras activity in tumor angiogenesis remains poorly understood. Using human pancreatic duct epithelial (HPDE) and K-Ras4BG12V–transformed HPDE (HPDE-KRas) cells, we show that activated K-Ras significantly enhanced the production of angiogenic factors including CXC chemokines and vascular endothelial growth factor (VEGF). Western blot analysis revealed that K-Ras activation promoted the phosphorylation of Raf/mitogen-activated protein kinase kinase-1/2 (MEK1/2) and expression of c-Jun. MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH2-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production. To further elucidate the biological functions of oncogenic K-Ras in promoting angiogenesis, we did in vitro invasion and tube formation assays using human umbilical vein endothelial cells (HUVEC). HUVEC cocultured with HPDE-KRas showed significantly enhanced invasiveness and tube formation as compared with either control (without coculture) or coculture with HPDE. Moreover, SB225002 (a CXCR2 inhibitor) and 2C3 (an anti-VEGF monoclonal antibody) either alone or in a cooperative manner significantly reduced the degree of both Ras-dependent HUVEC invasiveness and tube formation. Similar results were obtained using another pair of immortalized human pancreatic duct–derived cells, E6/E7/st and its oncogenic K-Ras variant, E6/E7/Ras/st. Taken together, our results suggest that angiogenesis is initiated by paracrine epithelial secretion of CXC chemokines and VEGF downstream of activated oncogenic K-Ras, and that this vascular maturation is in part dependent on MEK1/2 and c-Jun signaling. (Mol Cancer Res 2009;7(6):799–808)Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse modelBritish Journal of Cancer, 2007
- BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreasCancer Letters, 2007
- K-Ras Promotes Growth Transformation and Invasion of Immortalized Human Pancreatic Cells by Raf and Phosphatidylinositol 3-Kinase SignalingCancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Pancreatic Tumor Cells with Mutant K-ras Suppress ERK Activity by MEK-Dependent Induction of MAP Kinase Phosphatase-2Biochemical and Biophysical Research Communications, 2001
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996